My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

30.39 +1.09 (+3.72%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 21, 2023

Via Benzinga

Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 21, 2023

U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know ↗

September 19, 2023

Via Benzinga

EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug ↗

September 08, 2023

Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.

Via Benzinga

Analyst Ratings for Travere Therapeutics ↗

September 06, 2023

Via Benzinga

The Latest Analyst Ratings for Travere Therapeutics ↗

August 18, 2023

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

Expert Ratings for Travere Therapeutics ↗

July 18, 2023

Via Benzinga

Analyst Ratings for Travere Therapeutics ↗

June 07, 2023

Via Benzinga

3 Small-Cap Stocks That Could Be Big-Time Winners ↗

July 22, 2023

These stocks come with significant risks. But they could generate huge returns over time.

Via The Motley Fool

Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan ↗

July 21, 2023

Travere Therapeutics shares have lost nearly 30% since early May.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023 ↗

July 21, 2023

Via Benzinga

Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation ↗

July 17, 2023

Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...

Via Benzinga

11 Analysts Have This to Say About Travere Therapeutics ↗

May 22, 2023

Via Benzinga

Recap: Travere Therapeutics Q1 Earnings ↗

May 04, 2023

Via Benzinga

Earnings Outlook For Travere Therapeutics ↗

May 03, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 17, 2023

Via Benzinga

Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire ↗

July 05, 2023

Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.

Via Investor's Business Daily

3 Biotech Stocks That Could Skyrocket in the Next 12 Months ↗

June 07, 2023

These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.

Via InvestorPlace

3 Biotech Stocks With Blockbuster Potential ↗

May 24, 2023

Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 ↗

May 22, 2023

Via Benzinga

The Latest Analyst Ratings for Travere Therapeutics ↗

April 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 02, 2023

Via Benzinga

Chegg, Community Health Systems, Metropolitan Bank And Other Big Stocks Moving Lower On Tuesday ↗

May 02, 2023

U.S. stocks traded lower, with the Dow Jones losing around 477 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test ↗

May 02, 2023

Travere was testing a treatment for FSGS, a condition that causes kidney scarring.

Via Investor's Business Daily

Travere Therapeutics' Rare Kidney Disease Drug Disappoints In Phase 3 Study, Analyst Says Efficacy Trends Suggest Potential Path Forward ↗

May 02, 2023

Travere Therapeutics Inc (NASDAQ: TVTX) announced

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 02, 2023

Via Benzinga

Additional Data From Travere Therapeutics' Kidney Disease Candidate Reinforce Efficacy, Supporting Ongoing Launch ↗

April 03, 2023

Via Benzinga

3 Up-and-Coming Growth Stocks to Buy Right Now ↗

March 25, 2023

These companies are small now but could grow much larger over time.

Via The Motley Fool

3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing ↗

March 19, 2023

The high-flyers have soared to new heights and further gains could be up ahead.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.